問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Taipei Veterans General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

Recruiting Trial

876Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2213Cases

2019-06-30 - 2023-03-31

Phase I

A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP1948

Participate Sites
3Sites

Recruiting3Sites

2019-12-01 - 2022-12-20

Phase III

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

  • Condition/Disease

    Severe Vasomotor Symptoms (Hot Flashes)

  • Test Drug

    Fezolinetant

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated2Sites

2019-09-01 - 2022-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2006-06-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2006-06-30 - 2007-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2011-05-01 - 2013-04-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-01-01 - 2019-08-31

Phase I

A Phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy

  • Condition/Disease

    Advanced Malignancy

  • Test Drug

    LipoVNB Vinorelbine Tartrate

Participate Sites
2Sites

Terminated2Sites

顏厥全
Taipei Veterans General Hospital

Division of Hematology & Oncology

2013-09-03 - 2020-06-30

Phase I/II

A Phase I/II trial of TLC399 (ProDex) in Patients with Macular Edema due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability

  • Condition/Disease

    Macular Edema due to Retinal Vein Occlusion (RVO)

  • Test Drug

    TLC399 (ProDex)

Participate Sites
7Sites

Terminated7Sites

2015-04-01 - 2017-03-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-01-01 - 2020-03-31

Phase IV

A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients with Peripheral T-cell Lymphoma after Prior Therapy

  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    FOLOTYN Solution for intravenous injection

Participate Sites
11Sites

Terminated11Sites

1 200 201 202 203 204 222
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB